ASCO 2023 | Overall-survival analysis of ADAURA: osimertinib in resected EGFRm stage IB-IIIA NSCLC

Roy S. Herbst, MD, PhD, Yale School of Medicine, New Haven, CT, provides an overview of the overall-survival (OS) analysis from the Phase III ADAURA trial (NCT02511106) of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). The primary analysis showed a significant disease-free survival (DFS) benefit compared to placebo. An updated analysis with 2 years of additional follow-up confirmed sustained DFS and CNS DFS benefits. In this final analysis, the focus was on OS. Osimertinib demonstrated a highly significant and clinically meaningful OS benefit compared to placebo. In patients with stage II–IIIA disease, the hazard ratio (HR) for OS was 0.49, and the 5-year OS rate was 85% with osimertinib versus 73% with placebo. In the overall population (stage IB–IIIA), the OS HR was also 0.49, and the 5-year OS rate was 88% with osimertinib versus 78% with placebo. These results establish adjuvant osimertinib as an effective targeted treatment option for patients with EGFRm stage IB–IIIA NSCLC after complete tumor resection, regardless of adjuvant chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.